Clinical trials: Bladder Tumor
Hematuria, Urothelial Carcinoma
Urine DNA Methylation Detection for Hematuria Evaluation
Background: Hematuria, a common symptom of urinary system diseases, can result from various causes including infection, stones, trauma, and tumors.
- Conditions
- Hematuria, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
- Trial name
- NCT06427993
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Changhai Hospital
Head and Neck Neoplasms, Lung Neoplasms
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
Background: Two experimental drugs, FdCyd (also called 5-fluoro-2'-deoxcytidine), and THU (also called tetrahydrouridine), are undergoing trials to test their effectiveness in treating cancer that has not responded to standard…
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT00978250
- Testing
- 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Carcinoma
Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer
This study evaluates the general physical, emotional, and sexual function in women undergoing a radical cystectomy for bladder cancer.
- Trial name
- NCT05399004
- Testing
- Survey Administration
- Where
- 14 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Biliary Tract Cancer
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
The main purpose of this study is to determine if XL119 is more effective than the combination of 5-fluorouracil (5FU) and leucovorin (LV) in prolonging the survival of subjects with advanced biliary tumors.
- Trial name
- NCT00090025
- Testing
- becatecarin, 5-Fluorouracil Plus Leucovorin
- Where
- 59 sites in United States, Belgium and 9 more
- Volunteers
- 248 people
- Sponsor
- Helsinn Healthcare SA
Bladder Cancer
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
Patients older than ≥18 years, with muscle-invasive bladder cancer unfit for radical cystectomy because of age, comorbidities, and/or patient's refusal. This study is designed as a multicentre, single-arm phase II study.
- Trial name
- BladderSpar (NCT03697850)
- Testing
- Atezolizumab
- Where
- 12 sites in France
- Volunteers
- 79 people
- Sponsor
- UNICANCER
Bladder Cancer
Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers
The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments.
- Trial name
- GUB-BCR-001 (NCT03413982)
- Testing
- Registry
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Kansas Medical Center
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Bladder Cancer
Study With a Newly Optical Coherence Tomography Probe for Optimizing Bladder Cancer Diagnosis and Treatment
The goal of this clinical trial is to see if a new designed optical coherence tomography catheter can be used in bladder cancer in patients undergoing a transurethral resection of a bladder tumour.
- Trial name
- BLOCT (NCT06679920)
- Testing
- Optical coherence tomography
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Amsterdam UMC
Bladder Cancer
Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)
This study is being done to learn more about energy needs and muscle function during treatment for bladder cancer. These insights can help improve future patient care.
- Trial name
- METRICS (NCT06721260)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center
Bladder Cancer (BC)
Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC)
Recombinant oncolytic adenovirus injection (KD01) is an oncolytic virus product. Its main component is a conditionally replicative recombinant human type 5 adenovirus, where part of the E3 region has been replaced with the gene…
- Trial name
- NCT07359235
- Testing
- KD01(the recombinant oncolytic adenovirus)
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tongji Hospital
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Bladder Cancer, Urothelial Carcinoma Bladder
Bladder Cancer Adjuvant Radiotherapy Trial
Aim and objectives: This trial aims to evaluate the role of adjuvant radiotherapy following chemotherapy in patients with high-risk features on histo-pathology after radical surgery for transitional cell carcinoma of urinary…
- Trial name
- BART (NCT02951325)
- Testing
- Adjuvant RT
- Where
- India
- Volunteers
- 153 people
- Sponsor
- Tata Memorial Centre
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
- Trial name
- NCT01234519
- Testing
- AEZS-108, AEZS-108 at MTD
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- AEterna Zentaris
Bladder Cancer
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
The purposes of this study is to evaluate a new genetic-based test which will identify patients diagnosed with muscle-invasive bladder cancer before their surgery, who might have specific genes, which will increase their chances…
- Trial name
- NCT00918008
- Testing
- Blood draw
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
This is an interventional, prospective multicenter, open-label, phase II study in patients after curative surgery for BTC in a classic adjuvant situation, consisting of a two arm feasibility pilot part with a randomized…
- Conditions
- Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma
- Trial name
- NCT05239169
- Testing
- Durvalumab, Tremelimumab, Capecitabine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Bladder Cancer, Urinary Bladder Neoplasm
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
The purpose of this study is to examine the usefulness of implanting small 24-K gold fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify the original tumor location at the time of radiation…
- Conditions
- Bladder Cancer, Urinary Bladder Neoplasm, Urologic Neoplasms, Neoplasms
- Trial name
- FMBRT (NCT04442724)
- Testing
- Fiducial marker placement, Multiparametric MRI (mpMRI)
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cedars-Sinai Medical Center
Solid Tumours of Epithelial Origin, Metastatic Colorectal Cancer
Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients
This is a multicentre, open-label, Phase I/II study of enadenotucirev in patients with either solid tumour of epithelial origin not responding to standard therapy or for whom no standard treatment exists (Phase I dose escalation…
- Conditions
- Solid Tumours of Epithelial Origin, Metastatic Colorectal Cancer, Metastatic Bladder Cancer
- Trial name
- EVOLVE (NCT02028442)
- Testing
- Enadenotucirev
- Where
- 6 sites in Belgium, Spain
- Volunteers
- 61 people
- Sponsor
- Akamis Bio
Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
This phase II trial tests how well enfortumab vedotin (EV) and pembrolizumab works in treating patients with bladder cancer of variant histology (a group of less common types of bladder cancer) that have spread to nearby tissue…
- Conditions
- Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm
- Trial name
- NCT05756569
- Testing
- Biospecimen Collection, Computed Tomography, Enfortumab Vedotin
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Emory University